NanoTemper Technologies offers the Prometheus NT.48, with nanoDSF technology. nanoDSF is the method of choice for easy, rapid and accurate analysis of protein folding and stability. Applications include protein engineering, membrane protein research, formulation development and quality control.
Watch our short movie to learn how to easily run and analyze experiments on the Prometheus NT.48.
Ready to tackle your challenging stability characterizations?
Discover tools
42:49In this webinar Dr. Melanie McDowell, Research Group Leader at the MPI of Biophysics outlines bottlenecks associated with membrane protein purification for cryo EM and strategies to overcome them
When working with membrane proteins, whether you’re troubleshooting aggregation, testing new solubilization strategies, or deciding when to switch detergents read this guide for practical solutions.
Learn about Prometheus Panta C: A next-generation stability characterization platform that's helping biomanufacturers bring automation into the analytical core of their development and process control
Dr. Marius Müller of Johnson & Johnson Innovative Medicine shares insights from questions about the use of nanoDSF™ technology for ID-testing and at several late stages of biotherapeutics development.
53:00Explore a comprehensive, data-driven workflow—rooted in real-world results—combining the NativeMP platform with Prometheus Panta.
NanoTemper Technologies announces the launch of Prometheus Panta C, a solution designed to meet the evolving needs of biopharmaceutical development—from preclinical phase to commercial manufacturing.
Learn how to enhance your lab's efficiency with Prometheus Panta, from using capillary chips for high-throughput sample loading to solutions for seamless integration in automated workflows
Expert Marius Müller, PhD, Team Lead at Johnson & Johnson Innovative Medicine, shares insights into three significant trends that have potential to reshape the biopharma and biomanufacturing industry
1:45Increase your throughput, improve precision, and streamline your workflow by automating biologics characterization. Discover Prometheus Panta, an instrument for multi-parameter stability measurements
31:28Watch this webinar to discover how Dr. Marius Müller from Johnson & Johnson Innovative Medicine, uses nanoDSF, a high-throughput method that assesses protein stability, for drug substance ID testing.
Use this curated list of must-attend 2025 biologics conferences to plan your year. Find out when and where each conference takes place, who will be there, and what you can expect.
43:09Learn about technologies and instruments that maintain membrane protein stability and allow structural abd affinity screening studies in their natural lipid environment.
26:58Watch this webinar about approaches and insights into bispecific formulation development and screening with Prometheus Panta for thermal and colloidal stability characterization of biotherapeutics.
Learn how Pierre Fabre uses multi-parameter stability measurements of mAb libraries on Prometheus Panta to streamline developability platforms, reducing complexity, cost, and sample consumption.
Membrane proteins present challenges for structural analysis by cryo-EM; Screening of synthetic copolymers with nanoDSF and DLS on Prometheus Panta help select the best solubilization conditions.
Read why scientist Dr. Elsa Wagner chose the Prometheus Panta instrument with simultaneous measurements of DLS, nanoDSF, SLS and backreflection for developability assessment of their mAbs candidates.
4:51The decisions you make about your biologics candidates early in the pipeline ultimately affect their success as therapeutics. Combine sizing and stability information to develop successful biologics
9:42Your protein stability characterization projects require tools that provide high-precision, high-quality data to support your selection process. Watch this 10 min walkthrough of Prometheus Panta.
16:24Get developability profiles for monoclonal antibodies with stability data from Prometheus Panta to inform on rational design and selection of therapeutic constructs that will succeed in the clinic.
